The federal government's statement supporting a whistleblower's $40 billion False Claims Act suit against Celgene Corp. over the off-label promotion of cancer drugs Thalomid and Revlimid doesn't dismantle the company's arguments for dismissal because there's still no evidence of wrongdoing, Celgene told a California federal court Tuesday.





